RxDoctor Payments Data

Kacey Hu, MD

Neurology · Los Angeles, CANPI 1306211669

Payments from drug & device makers

$11,724in general payments, 2019–2025

Across 19 payments — averaging $617.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$10K
  • Abbott$1K
  • Ipsen Biopharmaceuticals, Inc$107
  • Teva Pharmaceuticals USA, Inc.$70
  • Biogen$67
  • UCB, Inc.$34
  • plus $52 from 2 others

What the payments were for

  • Grants$10,00085%
  • Travel & lodging$1,0469%
  • Food & beverage$4694%
  • Education$2092%

General payments by program year

20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,724 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$2,942
Medicare patients
17
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa103$162,123
GocovriAmantadine Hcl20$74,597
AustedoDeutetrabenazine11$49,921
Rasagiline Mesylate82$31,976
Carbidopa-LevodopaCarbidopa/Levodopa224$10,916
Carbidopa-Levodopa ErCarbidopa/Levodopa70$3,723
Entacapone18$3,641
Droxidopa12$2,607
AmantadineAmantadine Hcl47$2,348
Ropinirole ErRopinirole Hcl13$1,963
Quetiapine Fumarate24$1,608
RivastigmineRivastigmine Tartrate12$1,455
Ropinirole Hcl29$969
Propranolol Hcl32$586
Donepezil Hcl42$484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$70$49,92111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →